These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19243714)

  • 1. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment.
    Oberwittler H; Baccara-Dinet M
    Int J Clin Pract; 2006 Jun; 60(6):707-15. PubMed ID: 16805757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.
    Kamal-Bahl SJ; Burke TA; Watson DJ; Wentworth CE
    Curr Med Res Opin; 2008 Jun; 24(6):1817-21. PubMed ID: 18485268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aspirin on niacin-induced cutaneous reactions.
    Whelan AM; Price SO; Fowler SF; Hainer BL
    J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.
    Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ
    Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S; Simko RJ; Quimbo RM; Cziraky MJ
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to medications by patients after acute coronary syndromes.
    Sud A; Kline-Rogers EM; Eagle KA; Fang J; Armstrong DF; Rangarajan K; Otten RF; Stafkey-Mailey DR; Taylor SD; Erickson SR
    Ann Pharmacother; 2005 Nov; 39(11):1792-7. PubMed ID: 16204391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing.
    Banka SS; Thachil R; Levine A; Lin H; Kaafarani H; Lee J
    Am J Health Syst Pharm; 2017 Jun; 74(12):898-903. PubMed ID: 28432049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apple pectin for the reduction of niacin-induced flushing.
    Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K
    J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' perceptions and illness severity at start of antidepressant treatment in general practice.
    van Geffen EC; Heerdink ER; Hugtenburg JG; Siero FW; Egberts AC; van Hulten R
    Int J Pharm Pract; 2010 Aug; 18(4):217-25. PubMed ID: 20636673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors related to adherence to statin therapy.
    McGinnis B; Olson KL; Magid D; Bayliss E; Korner EJ; Brand DW; Steiner JF
    Ann Pharmacother; 2007 Nov; 41(11):1805-11. PubMed ID: 17925498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Jacobson TA
    Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.